ASH 2022 | Investigating the molecular and clinical features of FLT3-JMD mutations in AML
In this video, James Blachly, MD, The Ohio State University, Columbus, OH, speaks on the less common FLT3 mutation, FLT3 juxtamembrane domain (FLT3-JMD), and outlines a recent study which evaluated FLT3-JMD mutation in patients with newly diagnosed acute myeloid leukemia (AML). Dr Blachly highlights that the FLT3-JMD mutation is responsive to both type 1 and type 2 FLT3 inhibitors, suggesting that there are more potential treatment options for patients with this particular mutation. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
KITE Pharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees; INNATE Pharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees; AstraZeneca: Consultancy, Membership on an entity’s Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Astellas: Consultancy, Membership on an entity’s Board of Directors or advisory committees; MingSight Pharmaceuticals: Research Funding.
